Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

111
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linerixibat: First Approval.

Drugs·2026
Same author

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.

Targeted oncology·2026
Same author

Guselkumab: Pediatric First Approval.

Paediatric drugs·2026
Same author

Taletrectinib: First Approval.

Drugs·2025
Same author

Trastuzumab Rezetecan: First Approval.

Drugs·2025
Same author

Correction to: Revakinagene Taroretcel: First Approval.

Molecular diagnosis & therapy·2025

Related Experiment Video

Updated: Dec 8, 2025

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

847

Tafasitamab: First Approval.

Sheridan M Hoy1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|September 18, 2020
PubMed
Summary
This summary is machine-generated.

Tafasitamab, an anti-CD19 antibody, is approved with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults ineligible for stem cell transplant. This combination offers a new second-line treatment option.

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Experiment Videos

Last Updated: Dec 8, 2025

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

847
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
  • Relapsed or refractory DLBCL poses significant treatment challenges, especially for patients ineligible for autologous stem cell transplantation (ASCT).
  • Existing second-line treatment options for this patient population are limited.

Purpose of the Study:

  • To summarize the development milestones of tafasitamab.
  • To highlight the accelerated approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory DLBCL.
  • To provide an overview of tafasitamab's mechanism of action and its potential in other B-cell malignancies.

Main Methods:

  • Tafasitamab is an Fc-modified, humanized, anti-CD19 monoclonal antibody.
  • It targets the CD19 protein expressed on B-cells.
  • The study summarizes regulatory submissions and clinical investigation data.

Main Results:

  • Tafasitamab received accelerated approval in the USA in July 2020, in combination with lenalidomide.
  • This combination is indicated for adults with relapsed or refractory DLBCL not eligible for ASCT.
  • It represents the first approved second-line therapy for this specific patient group in the USA.

Conclusions:

  • Tafasitamab plus lenalidomide offers a novel therapeutic option for relapsed or refractory DLBCL patients.
  • Regulatory assessment for this combination is ongoing in the EU.
  • Tafasitamab is also under investigation for other B-cell malignancies, including follicular lymphoma.